1. 3rd column
What's happening with the consumer product segment and why healthcare industry firms are separating it ?
2. Is it likely that new consumer products company would add debt to generate cash for J&J
Is there going to be change in the name of both of businesses as they are saying that J&J is going to retain its pharma & medical device units?
Even though they are demerging, their revenue is expected to drop. How should an analyst see to it?
What is the strategy behind this M&A activity (by following Toshiba) and how an investor should see this as for analysis? in this pandemic the pharma companies are growing rapidly so this is the best time to demerge?
1. The article states that the new consumer business will be a publicly traded company so what about it's pharma business, will it remain private or go public?
2. Why did the company decide to demerge after its competitors and not earlier? If it only had to add value and allocate resources effectively it should have done it earlier only no?
3. Does 'unlocking significant value' mean manufacturing more unique in-house products?
Why have the 2 businesses diverged? (para 3)